Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "free cc dumps with pin, 【 Visit Amsiga.com 】 ojM3t2s., dumpscvv, buy bin cc, rescator shop LfYM"

Looking for quality documents?
external link icon
Repligen Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
—Record revenue of $206.4 million for the quarter, and year-over-year growth of 45% as reported and 48% at constant currency —Organic revenue growth of 44% for the quarter and base business growth of 37% —Growth driven by combination of base business strength, COVID-related demand, and acquisition revenue
WALTHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2022. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2022 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We delivered on another outstanding quarter for the company with over $206 million in revenue and 44% organic growth. We were especially pleased with the momentum in our base business, which delivered
external link icon
Repligen Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Financial Guidance
Reported revenue was $142.8 million for the quarter, representing year-over-year growth of 88% and organic growth of 69%
Growth driven by combination of COVID-related demand, base business strength and acquisition revenue WALTHAM, Mass., May 04, 2021 (GLOBE NEWSWIRE) -   Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter ended March 31, 2021. Provided in this press release are financial highlights for the quarter, updates to our financial guidance for the year 2021, and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I am extremely proud of the way our team executed here in the first quarter.  With unprecedented demand driven by strong COVID tailwinds, our whole team pivoted to deliver an impressive quarter with 88% growth and 69% organic. COVID revenue contribution ticked up to 25%
external link icon
Repligen Receives Complete Response Letter from FDA for RG1068 NDA
Repligen Corporation (NASDAQ:RGEN) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) regarding the Company’s New Drug Application (NDA) for RG1068 (synthetic human secretin). RG1068 was evaluated in a Phase 3 study to improve detection of pancreatic duct abnormalities in combination with MRI in patients with known or suspected pancreatitis. The CRL indicates that the FDA has completed its review of the RG1068 NDA and has determined that additional clinical efficacy and safety trial data will be required to support potential approval of the NDA. There were no specific safety concerns cited in the CRL, although safety will continue to be monitored in conjunction with any future clinical trial. No deficiencies were cited in the CRL with respect to the manufacturing, pharmacology or toxicology sections of the NDA. “We will continue to engage in dialogue with the FDA to determine the design and scope of a clinical
external link icon
Repligen Acquires Atoll GmbH
WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has acquired Atoll GmBH (“Atoll”) of Weingarten, Germany, an innovator and manufacturer of MediaScout® pre-packed chromatography columns used in process development and clinical manufacturing of biologic drugs. The acquisition of Atoll expands Repligen’s pre-packed column chromatography portfolio into high throughput process development screening, complementing the Company’s existing strength in clinical production-scale columns. The combined offering will provide bioprocessing customers with breadth and flexibility in choosing column size, chromatography media and packed bed formats.   Repligen purchased Atoll from UV-Cap GmbH & Co. KG on April 1, 2016 for a combination of $9.1 million in cash and 538,700 shares 1  of Repligen common stock, for total upfront consideration of approximately
event icon
How Small-Scale Chromatography Models Transform mAb Viral Clearance and Process Characterization
Watch this webinar with Matt Taylor, Senior Process Development Associate at KBI Biopharma, to see how pre-packed chromatography columns can provide reliable small-scale models of the downstream mAb purification process. You’ll learn: How pre-packed columns deliver equivalent viral clearance performance, even with aged resin Ways to streamline experimental workflows, reduce operational preparation times, and enhance productivity while adhering to ICH Q5A guidelines How eliminating column packing and validation steps frees teams to focus on higher-value activities
external link icon
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
Proposed acquisition adds novel macroporous chromatography base bead technology for downstream bioprocess applications
Accelerates expansion into new modality markets with a unique, scalable purification solution Strongly synergistic with AVIPure ® affinity ligands and OPUS ® pre-packed chromatography columns
WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a definitive agreement to acquire privately-held Tantti Laboratory Inc. (“Tantti”) of Taoyuan City, Taiwan. Tantti has developed a unique portfolio of macroporous chromatography beads to optimize the purification of new modalities including viral vectors, viruses, nucleic acids and other large molecule biologics. Tantti’s DuloCore ® technology platform combines the high throughput performance of membranes with the rapid mass transfer of monoliths in a
external link icon
Repligen Selects Purolite Life Sciences as Commercial Partner for New High Performance Ligand
WALTHAM, Mass., June 28, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact™ A,  which will be commercialized by Purolite Life Sciences using their novel Praesto® agarose jetting base bead technology. Repligen is a longtime market leader in Protein A, with two facilities that produce the majority of the global Protein A ligand demand to biopharmaceutical customers worldwide. NGL-Impact™ A was developed as part of Repligen’s collaboration with Navigo Proteins GmbH. This new ligand has outstanding performance attributes when immobilized on jetted agarose bead technology, with ultra-high binding capacities and excellent alkaline stability. These attributes are important in providing improved monoclonal antibody capture to handle increased upstream product titres, and in
event icon
Antibody–Drug Conjugate Manufacturing: Driving Process Productivity and Reducing Risk
In this webinar, Field Applications Scientists Zoltán Gulyás and Nigel Herbert discuss how innovative technologies can help ADC manufacturers overcome common process hurdles. Through three real-world case studies, you’ll learn how to: Accelerate processing time and minimize risk to product and operators during tangential flow filtration (TFF) Maintain product consistency and operator safety while minimizing extractables and leachables. Drive process efficiency and reduce turnaround time with accurate, real-time DAR measurement
external link icon
Repligen Reports Second Quarter 2020 Financial Results and Updates Full Year 2020 Financial Guidance
Reports record quarterly revenue of $87.5 million
Overall revenue grew 24% year-over-year, with organic growth of 19% Raises revenue guidance to $332-$340 million for full year 2020, representing 18%-21% organic growth Completes acquisition of silicone molding and tubing manufacturer Engineered Molding Technology WALTHAM, Mass., July 30, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2020. Provided in this press release are financial highlights for the three- and six- month periods ended June 30, 2020, updates to our financial guidance for the fiscal year 2020 and access information for today’s webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “I’m pleased to report that the company delivered outstanding financial performance during the second quarter as we continue to focus on keeping all our
corporate icon
Plasmid DNA Purity
Challenge: Assessing pDNA purity is critical for gene therapy but traditional assays are slow and reagent-heavy. Our Solution: SoloVPE PLUS delivers fast, dilution-free A260/A280 ratio measurements for rapid purity checks.
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support